Crohn Disease
📧 Sign up to get email alerts when something new happens for Crohn Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Impact of Telemonitoring in the Management of Complex IBD in Spain: M-TECCU [NA]
A completed clinical trial evaluating telemonitoring in the management of complex inflammatory bowel disease (Crohn's disease and ulcerative…
-
EMA approval · 2026-02-05EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) as a biosimilar of adalimumab for several inflammatory and autoimmune diseases, including rheumatoid art…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Pregnancy and Inflammatory Bowel Disease
Centre Hospitalier Universitaire, Amiens is sponsoring a recruiting clinical trial addressing inflammatory bowel disease in pregnancy. The s…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Patients [Phase 2]
A Phase 2 clinical trial is investigating quality of life during Crohn's disease flares when treated with prednisolone versus an anti-CCrohn…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Uneven Nutrition and Life Style as IBD Triggers in Adolescents and Adults [NA]
A clinical trial examining whether uneven nutrition and lifestyle factors trigger Crohn's disease or ulcerative colitis in adolescents and a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-02-04EMA Authorised: Imraldi (adalimumab) — Samsung Bioepis NL B.V.
EMA authorised Imraldi, a biosimilar adalimumab by Samsung Bioepis NL B.V., for multiple inflammatory diseases including ankylosing spondyli…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Relationships of B-cell Activating Factor Gene Polymorphisms With Crohn's Disease.
A completed clinical study examining the relationship between B-cell activating factor (BAFF) gene polymorphisms and Crohn's disease.
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease. [NA]
This clinical trial aims to identify fecal microbiota biomarkers of spondyloarthritis in patients with Crohn's disease and is currently recr…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Analysis of Barriers and Facilitators to Adapted Physical Activity for Pediatric Patients With Chronic Inflammatory Bowel Diseases
Clinical trial update describing a study that analyzes barriers and facilitators to adapted physical activity for pediatric patients with ch…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
An ongoing trial evaluating whether prophylactic dexamethasone before infliximab infusions improves outcomes or reduces reactions in moderat…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Low Dose IL-2 for the Treatment of Crohn's Disease [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating low-dose interleukin-2 for Crohn's disease is currently recruiting.
-
FDA approval · 2026-02-02FDA Approved: TYRUKO — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for TYRUKO (natalizumab-sztn) from Sandoz Inc, updating the regulatory file for this biosimilar unde…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Specific Dietary Pattern for Crohn's Disease Patients Following Surgery [NA]
This update notes an ongoing clinical trial evaluating a specific dietary pattern for Crohn's disease patients after surgery. The study is c…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Expanded Access to Upadacitinib
AbbVie’s expanded access program for Upadacitinib is currently AVAILABLE for patients with Crohn's disease, ulcerative colitis, juvenile idi…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility [NA]
Clinical trial update announcing ongoing recruitment for PRE-Crohn's, a study evaluating personalized risk estimation in Crohn's disease. Sp…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: PRecisiOn Microbiome Directed ExtensiOn of Anti-TNFα Crohn's Disease ThErapy in Children: The PROMOTE Trial [NA]
The PROMOTE trial investigates a precision, microbiome-directed extension of anti-TNFα therapy for pediatric Crohn's disease; the study is c…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Resistant Starch in Pediatric Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) [NA]
This is an update on a pediatric clinical trial evaluating resistant starch for Crohn's disease and ulcerative colitis at the Children's Hos…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: OptiMized REsistaNt Starch in Inflammatory Bowel Disease: The MEND Trial [NA]
The MEND Trial evaluating OptiMized Resistant Starch for inflammatory bowel disease is listed as active but not recruiting. Target condition…
-
EMA approval · 2026-01-28EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EMA authorised Hukyndra (adalimumab) from Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, psoriati…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Performance of Non-injected MR Enterography Compared to a Conventional MR Enterography Protocol With Contrast Agent Injection
A completed clinical trial comparing non-injected MR enterography with a conventional contrast-enhanced MR enterography protocol to assess p…
-
CLINICAL_TRIALS other · 2026-01-28Clinical Trial Update: Optoacoustic Detection of Inflammation Using MSOT Device [NA]
Clinical trial investigating an MSOT optoacoustic device for detecting inflammation in graft-versus-host disease, colitis, and Crohn's disea…
-
EMA approval · 2026-01-27EMA Authorised: Cimzia (certolizumab pegol) — UCB Pharma
The European Medicines Agency authorised Cimzia (certolizumab pegol) for treatment of rheumatoid arthritis and other inflammatory diseases, …
-
CLINICAL_TRIALS withdrawal · 2026-01-27Clinical Trial Update: AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE) [Phase 1]
A Phase 1 trial evaluating allogeneic human mesenchymal stem cells for fistulizing Crohn's disease via perifistula injections has been withd…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease [NA]
A prospective randomized study comparing epigenetic-marker–guided treatment selection to standard of care in adults with Crohn's disease is …
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease
This clinical trial update aims to describe epidemiological characteristics and evaluate the efficacy of interventions for difficult-to-trea…